vTv Therapeutics (VTVT) Reports Q2 Loss of $0.47/Share

vTv Therapeutics (NASDAQ: VTVT) reported Q2 EPS of ($0.47). Revenue for the quarter came in at $182 thousand, versus $110 thousand reported last year.

Cash, cash equivalents and marketable securities as of June 30, 2016 were $63.8 million, compared to $88.0 million as of December 31, 2015. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through at least mid-2017.

For earnings history and earnings-related data on vTv Therapeutics (VTVT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
• Ennis (EBF) Reports In-Line Q1 EPS